Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial ...

Insilico Medicine has signed a deal worth up to $600 million with Takeda to collaborate on asset discovery across the Japan Big Pharma's therapeutic areas of interest.  | Insilico Medicine has signed ...

AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 b | AbbVie has struck a deal to buy Apogee Therapeutics for $10 ...

United Therapeutics has paid $140 million to buy Thymmune Therapeutics for preclinical regenerative cell therapies focused on the thymus.

Insillico Medicine and SK Biopharmaceuticals have teamed up on an AI-enabled search for drug candidates targeting neuroimmune ...

AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug ...

When writing a blockbuster movie script, screenplay writers are sure to include all the essential elements of a hit | The ...

The beleaguered genomic medicine biotech Sangamo has traveled a rough road lately, with recent years | Eli Lilly and Astellas ...

Five months after Corxel Pharmaceuticals reeled in hundreds of millions of dollars to support further development of its oral ...

Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

With pharma heavyweights clashing against one another and reeling in major sales in the ulcerative colitis (UC) | Merck is ...